KR20210031852A - 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료 - Google Patents
종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료 Download PDFInfo
- Publication number
- KR20210031852A KR20210031852A KR1020207025771A KR20207025771A KR20210031852A KR 20210031852 A KR20210031852 A KR 20210031852A KR 1020207025771 A KR1020207025771 A KR 1020207025771A KR 20207025771 A KR20207025771 A KR 20207025771A KR 20210031852 A KR20210031852 A KR 20210031852A
- Authority
- KR
- South Korea
- Prior art keywords
- adenovirus
- inhibitor
- cdk4
- cells
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020267017074A KR20260089640A (ko) | 2018-03-05 | 2019-03-05 | 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18000210 | 2018-03-05 | ||
| EP18000210.7 | 2018-03-05 | ||
| PCT/EP2019/000067 WO2019170283A1 (en) | 2018-03-05 | 2019-03-05 | Treatment of tumors by a combination of an oncolytic adenovirus and a cdk4/6 inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267017074A Division KR20260089640A (ko) | 2018-03-05 | 2019-03-05 | 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210031852A true KR20210031852A (ko) | 2021-03-23 |
Family
ID=61569019
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207025771A Ceased KR20210031852A (ko) | 2018-03-05 | 2019-03-05 | 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료 |
| KR1020267017074A Pending KR20260089640A (ko) | 2018-03-05 | 2019-03-05 | 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020267017074A Pending KR20260089640A (ko) | 2018-03-05 | 2019-03-05 | 종양 세포 붕괴성 아데노바이러스와 cdk4/6 억제제의 조합물에 의한 종양의 치료 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210038661A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3762004B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2021517119A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20210031852A (cg-RX-API-DMAC7.html) |
| CN (1) | CN112533620B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019232768B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3092907A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3762004T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2965632T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3762004T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE064471T2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202007873VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019170283A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210066635A (ko) * | 2019-11-28 | 2021-06-07 | 의료법인 성광의료재단 | 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021044061A1 (en) * | 2019-09-05 | 2021-03-11 | Klinikum Rechts Der Isar Der Technischen Universität München | Treatment of tumors by a combination of an oncolytic adenovirus, a cdk4/6 inhibitor and a further therapeutically active agent |
| EP4578943A4 (en) * | 2022-08-25 | 2026-02-25 | Fujifilm Corp | PROCESS FOR TARGETING VIRUS PRODUCTION AND CULTURE COMPOSITION |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318832T1 (de) | 1990-06-11 | 2006-03-15 | Gilead Sciences Inc | Verfahren zur vervendung von nukleinsäureliganden |
| ES2188985T3 (es) | 1996-08-30 | 2003-07-01 | Jens Peter Furste | Seleccion enantiomerica y evolucion enantiomerica de acidos nucleicos. |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU2003242585A1 (en) | 2002-05-27 | 2003-12-12 | Per Sonne Holm | Novel use of adenoviruses and nucleic acids coding therefor |
| PL219321B1 (pl) * | 2002-10-15 | 2015-04-30 | Per Sonne Holm | Adenowirus, kodujący go kwas nukleinowy, zawierający je układ replikacyjny, wektor, komórka i organizm, ich zastosowanie oraz środek farmaceutyczny |
| WO2005052143A2 (de) * | 2003-11-14 | 2005-06-09 | Per Sonne Holm | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
| WO2012022496A2 (en) * | 2010-08-19 | 2012-02-23 | Per Sonne Holm | Method for killing tumor stem cells |
| US9271988B2 (en) * | 2011-07-01 | 2016-03-01 | Novartis Ag | Combination therapy comprising a CDK4/6 inhibitor and a P13K inhibitor for use in the treatment of cancer |
| SG11201507393TA (en) * | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| AU2014272695B2 (en) * | 2013-05-28 | 2016-10-20 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as BET inhibitors and their use in the treatment of disease |
| CN105899212A (zh) * | 2013-08-06 | 2016-08-24 | 翁科埃斯克斯有限公司 | 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法 |
| RU2670762C2 (ru) * | 2013-12-31 | 2018-10-25 | Хуаньчжу Фарма Ко., Лтд. | Производные 6-(пиримидиноаминопиридин)бензоимидазола, полезные для лечения рака |
| JP2017516862A (ja) * | 2014-05-30 | 2017-06-22 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲン受容体調節物質及びその使用方法 |
| CN107849111B (zh) * | 2015-05-04 | 2022-02-22 | Vcn生物科学有限公司 | 在免疫显性腺病毒抗原表位中具有突变的溶瘤腺病毒及其在癌症治疗中的用途 |
-
2019
- 2019-03-05 SG SG11202007873VA patent/SG11202007873VA/en unknown
- 2019-03-05 DK DK19710999.4T patent/DK3762004T3/da active
- 2019-03-05 US US16/978,048 patent/US20210038661A1/en active Pending
- 2019-03-05 KR KR1020207025771A patent/KR20210031852A/ko not_active Ceased
- 2019-03-05 JP JP2020546331A patent/JP2021517119A/ja active Pending
- 2019-03-05 CN CN201980016785.2A patent/CN112533620B/zh active Active
- 2019-03-05 EP EP19710999.4A patent/EP3762004B1/en active Active
- 2019-03-05 KR KR1020267017074A patent/KR20260089640A/ko active Pending
- 2019-03-05 WO PCT/EP2019/000067 patent/WO2019170283A1/en not_active Ceased
- 2019-03-05 HU HUE19710999A patent/HUE064471T2/hu unknown
- 2019-03-05 CA CA3092907A patent/CA3092907A1/en active Pending
- 2019-03-05 ES ES19710999T patent/ES2965632T3/es active Active
- 2019-03-05 AU AU2019232768A patent/AU2019232768B2/en active Active
- 2019-03-05 FI FIEP19710999.4T patent/FI3762004T3/fi active
-
2024
- 2024-10-23 JP JP2024186627A patent/JP2025013934A/ja active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210066635A (ko) * | 2019-11-28 | 2021-06-07 | 의료법인 성광의료재단 | 암 치료제에 대한 내성 암의 진단을 위한 조성물, 키트 및 방법 |
| KR20210154954A (ko) * | 2019-11-28 | 2021-12-21 | 의료법인 성광의료재단 | Prb4를 포함하는 내성 암 진단용 바이오마커 조성물 및 이의 용도 |
| KR20210154955A (ko) * | 2019-11-28 | 2021-12-21 | 의료법인 성광의료재단 | Smpd1를 포함하는 내성 암 진단용 바이오마커 조성물 및 이의 용도 |
| KR20210156258A (ko) * | 2019-11-28 | 2021-12-24 | 의료법인 성광의료재단 | Snora14b를 포함하는 내성 암 진단용 바이오마커 조성물 및 이의 용도 |
| KR20210156259A (ko) * | 2019-11-28 | 2021-12-24 | 의료법인 성광의료재단 | Acly를 포함하는 내성 암 진단용 바이오마커 조성물 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019170283A8 (en) | 2019-11-07 |
| CA3092907A1 (en) | 2019-09-12 |
| CN112533620A (zh) | 2021-03-19 |
| AU2019232768B2 (en) | 2025-12-18 |
| HUE064471T2 (hu) | 2024-03-28 |
| EP3762004B1 (en) | 2023-09-13 |
| EP3762004A1 (en) | 2021-01-13 |
| DK3762004T3 (da) | 2023-11-27 |
| AU2019232768A1 (en) | 2020-09-03 |
| CN112533620B (zh) | 2025-03-28 |
| US20210038661A1 (en) | 2021-02-11 |
| SG11202007873VA (en) | 2020-09-29 |
| ES2965632T3 (es) | 2024-04-16 |
| KR20260089640A (ko) | 2026-06-15 |
| RU2020132466A (ru) | 2022-04-05 |
| JP2025013934A (ja) | 2025-01-28 |
| RU2020132466A3 (cg-RX-API-DMAC7.html) | 2022-04-05 |
| WO2019170283A1 (en) | 2019-09-12 |
| FI3762004T3 (fi) | 2023-12-11 |
| JP2021517119A (ja) | 2021-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy | |
| Alonso et al. | ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo | |
| JP6072414B2 (ja) | 腫瘍選択的e1aおよびe1b変異体 | |
| Wang et al. | Chimeric 5/35 adenovirus-mediated Dickkopf-1 overexpression suppressed tumorigenicity of CD44+ gastric cancer cells via attenuating Wnt signaling | |
| JP2025013934A (ja) | 腫瘍溶解性アデノウイルスとcdk4/6阻害剤との組み合わせによる腫瘍の処置 | |
| US20090270484A1 (en) | WWOX Vectors and Uses in Treatment of Cancer | |
| JP2007511211A (ja) | アデノウイルスおよびそれをコードしている核酸の新たな使用 | |
| JP2007511212A (ja) | 新規アデノウイルス、それをコードする核酸及びその使用 | |
| US20080089864A1 (en) | Adenoviruses mutated in the VA genes for cancer treatment | |
| Holzmüller et al. | YB‐1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma | |
| JP7834342B2 (ja) | 腫瘍溶解性アデノウイルスと、cdk4/6阻害剤と、更なる治療的に活性な薬剤との組み合わせによる腫瘍の処置 | |
| Yoo et al. | Vaccinia virus‐mediated cell cycle alteration involves inactivation of tumour suppressors associated with Brf1 and TBP | |
| RU2811278C2 (ru) | Лечение опухолей комбинацией онколитического аденовируса и ингибитора cdk4/6 | |
| RU2835886C1 (ru) | Лечение опухолей комбинацией онколитического аденовируса, ингибитора cdk4/6 и дополнительного терапевтического агента | |
| Wang et al. | HSF1 overexpression enhances oncolytic effect of replicative adenovirus | |
| Guo et al. | Antiglioma effects of combined use of a baculovirual vector expressing wild‐type p53 and sodium butyrate | |
| Srivastava et al. | Mode of cell death associated with adenovirus-mediated suicide gene therapy in HNSCC tumor model | |
| Ge et al. | A novel role mediated by adenoviral E1A in suppressing cancer through modulating decorin | |
| Li et al. | microRNA response element‑regulated TIKI2 expression suppresses the tumorigencity of malignant gliomas | |
| Majhen et al. | Vincristine-resistant human laryngeal carcinoma cells demonstrate increased Rous sarcoma virus promoter activity | |
| Cabrele et al. | 5-Fluorouracil-related enhancement of adenoviral infection is Coxsackievirus-adenovirus receptor independent and associated with morphological changes in lipid membranes | |
| Rivera Gonzalez | Regulation of the prostate-specific hTGP (TGM4) gene and its potential use for prostate cancer gene therapy | |
| Zhang | TALEN-mediated site-specific integration of human CFTR gene by a helper-dependent adenoviral vector | |
| Aguirre | The oncolytic adenoviral AdΔΔ mutant sensitizes prostate cancer cells to mitoxantrone by promoting apoptosis and attenuating autophagy | |
| Wang et al. | Research HSF1 overexpression enhances oncolytic effect of replicative adenovirus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13 | Administrative time limit extension granted |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |
|
| A16 | Divisional, continuation or continuation in part application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 |